Diploma PLC (LON:DPLM - Get Free Report)'s share price traded up 0% on Wednesday . The stock traded as high as GBX 4,870 ($65.22) and last traded at GBX 4,862 ($65.11). 11,755,861 shares changed hands during trading, an increase of 1,962% from the average session volume of 570,053 shares. The stock had previously closed at GBX 4,860 ($65.09).
Diploma Stock Performance
The company's 50-day moving average price is GBX 3,949.28 and its two-hundred day moving average price is GBX 4,253.28. The company has a debt-to-equity ratio of 62.17, a quick ratio of 0.80 and a current ratio of 2.17. The stock has a market cap of £6.46 billion, a PE ratio of 55.70, a PEG ratio of 2.82 and a beta of 0.75.
Diploma (LON:DPLM - Get Free Report) last posted its quarterly earnings data on Wednesday, May 21st. The company reported GBX 80.20 ($1.07) earnings per share for the quarter. Diploma had a net margin of 9.25% and a return on equity of 13.18%. On average, equities research analysts forecast that Diploma PLC will post 163.7995512 EPS for the current year.
Insider Activity
In other Diploma news, insider David S. Lowden bought 750 shares of the firm's stock in a transaction that occurred on Friday, March 21st. The shares were bought at an average price of GBX 3,928 ($52.60) per share, for a total transaction of £29,460 ($39,453.60). Also, insider Ian El-Mokadem bought 500 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The stock was acquired at an average price of GBX 3,948 ($52.87) per share, for a total transaction of £19,740 ($26,436.32). Corporate insiders own 0.52% of the company's stock.
About Diploma
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
